IDEC-CE9 data

IDPH and SmithKline Beecham Pharmaceuticals announced that Phase II results show improved symptoms when the Primatized MAb was given to patients with RA. Data

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE